PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25637482-4 2015 We found a strong immune response in the gut of mice treated with MPTP, as demonstrated by the prominent presence of macrophages derived from CD115(+) CD11b(+) Ly6C(Hi) monocytes, known as M1 monocytes, and increased production of IL-1beta and IL-6. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 66-70 interleukin 6 Mus musculus 244-248 22772723-3 2012 In vivo, MPTP intoxication is accompanied by a strong microglia response which is characterised by the release of inflammatory molecules such as tumour necrosis factor alpha (TNF-alpha) and interleukin-6 (IL6) that are believed to further drive inflammation-mediated degeneration of mDA neurons. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 9-13 interleukin 6 Mus musculus 190-203 24995576-5 2014 The administration of MPTP (30 mg/kg for four successive days) significantly induced motor impairments as determined by behavioral studies (narrow beam test, catalepsy and akinesia), lowered dopamine levels and up-regulated the expressions of the inflammatory and apoptotic markers (tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, inducible nitric oxide synthase, glial fibrillary acidic protein, cyclooxygenase-2 and Bax). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 22-26 interleukin 6 Mus musculus 331-344 22772723-3 2012 In vivo, MPTP intoxication is accompanied by a strong microglia response which is characterised by the release of inflammatory molecules such as tumour necrosis factor alpha (TNF-alpha) and interleukin-6 (IL6) that are believed to further drive inflammation-mediated degeneration of mDA neurons. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 9-13 interleukin 6 Mus musculus 205-208 17574387-6 2007 The pre-intake of NAC, SEC, SMC, and SPC significantly attenuated MPTP-induced glutathione loss, retained the activity of GPX and SOD, diminished oxidative stress, and suppressed MPTP-induced elevation of IL-6 and TNF-alpha (P < 0.05). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 179-183 interleukin 6 Mus musculus 205-209 21970803-4 2011 MPTP treatment enhanced the release of interleukin (IL)-1beta, IL-6, tumor necrosis factor (TNF)-alpha, IL-4 and IL-10 (P < 0.05). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 0-4 interleukin 6 Mus musculus 63-67 20938211-5 2011 In MPTP-treated animals we observed a significant increase in IL-1beta, TNF-alpha and IL-6 mRNA expression levels both in the SN and CP in comparison with untreated mice. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 3-7 interleukin 6 Mus musculus 86-90 20925384-3 2010 MPTP treatment significantly depleted striatal glutathione content, reduced the activity of glutathione peroxidase (GPX), superoxide dismutase (SOD), and catalase, increased malondialdehyde and reactive oxygen species levels, and elevated interleukin-6, nitrite, and tumor necrosis factor-alpha production as well as enhanced inducible nitric oxide synthase (iNOS) activity in the striatum (P < 0.05). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 0-4 interleukin 6 Mus musculus 239-252 20333481-10 2010 The levels of proinflammatory cytokines (interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha) in the SN were also decreased and induced by MPTP. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 154-158 interleukin 6 Mus musculus 61-107 17574387-5 2007 RESULTS: The MPTP treatment significantly depleted striatal glutathione content, reduced the activity of glutathione peroxidase (GPX), superoxide dismutase (SOD), and catalase, increased malondialdehyde level, and elevated interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels in striatum (P < 0.05). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 13-17 interleukin 6 Mus musculus 223-236 17574387-5 2007 RESULTS: The MPTP treatment significantly depleted striatal glutathione content, reduced the activity of glutathione peroxidase (GPX), superoxide dismutase (SOD), and catalase, increased malondialdehyde level, and elevated interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels in striatum (P < 0.05). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 13-17 interleukin 6 Mus musculus 238-242 15862160-7 2005 RESULTS: Plasma IL-6 level in normal control mice was low, but elevated dramatically at 14 days after last time injection of MPTP in PD model mice. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 125-129 interleukin 6 Mus musculus 16-20 15910760-7 2005 The results showed that after MPTP treatment, striatal DA content was dramatically decreased, IL-1beta levels increased on day 3, while IL-6 levels increased on day 14. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 30-34 interleukin 6 Mus musculus 136-140 15910760-12 2005 These results have clearly demonstrated our hypotheses, that MPTP can induce increase of plasma IL-1beta and IL-6 levels in mice, and this effect is shaped by behavioral lateralization. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 61-65 interleukin 6 Mus musculus 109-113 18196934-10 2007 MPTP caused an increase in IL-6 in males and females, but this increase was significantly higher in females. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 0-4 interleukin 6 Mus musculus 27-31 15862160-0 2005 [Kinetic changes of plasma IL-1 and IL-6 levels in MPTP-induced Parkinson"s disease model mice and their relationship with brain asymmetry]. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 51-55 interleukin 6 Mus musculus 36-40 15862160-10 2005 CONCLUSION: IL-6 and IL-1 probably participate in the occurrence and progress of MPTP-induced PD in model mice, and were related with brain asymmetry. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 81-85 interleukin 6 Mus musculus 12-16 15804595-2 2005 The absence of interleukin-6 (IL-6) results in increased vulnerability of dopaminergic neurons to the neurotoxicant, MPTP, and a compromised reactive microgliosis. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 117-121 interleukin 6 Mus musculus 15-28 15804595-2 2005 The absence of interleukin-6 (IL-6) results in increased vulnerability of dopaminergic neurons to the neurotoxicant, MPTP, and a compromised reactive microgliosis. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 117-121 interleukin 6 Mus musculus 30-34 12957371-3 2003 We have previously shown that in the absence of interleukin-6 (IL-6) dopaminergic neurons are more vulnerable to MPTP. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 113-117 interleukin 6 Mus musculus 63-67 15589033-8 2005 The results showed that MPTP treatment induced dramatic loss of DA in striatum, simultaneously, IL-6 levels decreased in the striatum and increased in hippocampus and hypothalamus, while IL-1beta levels decreased in the striatum, cerebral cortex and hippocampus. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 24-28 interleukin 6 Mus musculus 96-100 16219171-1 2004 The work is to explore the relationship between the levels of cytokines (IL-1beta and IL-6) in C57BL/6J mice treated with MPTP and brain lateralization. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 122-126 interleukin 6 Mus musculus 86-90 16219171-6 2004 The plasma level of IL-6 was lower in left-pawed than that in right-pawed mice (p < 0.005) after MPTP treatment. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 100-104 interleukin 6 Mus musculus 20-24 16219171-10 2004 In conclusion, the level of plasma IL-6 of C57BL/6J mice treated with MPTP increased. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 70-74 interleukin 6 Mus musculus 35-39 12957371-7 2003 Extensive reactive microgliosis was observed in the SNpc of MPTP-lesioned IL-6 (+/+) mice. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 60-64 interleukin 6 Mus musculus 74-78 35366203-5 2022 MPTP administration also showed significant imbalance of inflammatory (increased TNF-alpha, IL-6 and NF-kappab) versus anti-inflammatory cytokines (decreased IL-10 levels). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 0-4 interleukin 6 Mus musculus 92-96 12358740-0 2002 Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 51-55 interleukin 6 Mus musculus 65-78 12358740-5 2002 Co-localization experiments identified striatal astrocytes as the source of IL-6 in IL-6 (+/+) mice at 1 and 7 days postinjection of MPTP. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 133-137 interleukin 6 Mus musculus 76-80 10499156-0 1999 Elevation of striatal interleukin-6 and serum corticosterone contents in MPTP-treated mice. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 73-77 interleukin 6 Mus musculus 22-35 10499156-8 1999 Increases in IL-6 were observed on days 1 and 7 post-MPTP. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 53-57 interleukin 6 Mus musculus 13-17 10499156-14 1999 These results suggest that changes in striatal IL-6 and serum corticosterone are closely associated with the severity of MPTP-induced dopaminergic degeneration. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 121-125 interleukin 6 Mus musculus 47-51 34850494-8 2022 Additionally, levels of dopamine were significantly reduced, and pro-inflammatory mediators tumor necrosis factor alpha (TNF-alpha), IL-1beta, IL6 were found to be increased in MPTP-induced C57BL6 PD mice. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 177-181 interleukin 6 Mus musculus 143-146 33784949-9 2021 The IL-6 expression in blood detected using ELISA was significantly reduced compared with MPTP group. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 90-94 interleukin 6 Mus musculus 4-8 31251998-6 2019 Moreover gliotic specific inflammatory markers like glial fibrillary acidic protein (GFAP), ionized calcium-binding adaptor protein-1 (Iba-1), iNOS and COX-2 were found to be expressed more in MPTP intoxicated mice, Further the levels of proinflammatory cytokines like IL-beta, IL-6, and TNF-alpha were significantly upregulated in MPTP intoxicated mice, these deleterious responses were diminished to extend neuroprotection by PHL treatment. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 193-197 interleukin 6 Mus musculus 278-282 31732967-7 2020 Furthermore, the increments of pro-inflammatory cytokines (TNF-alpha, IL-1beta and IL-6) and TUNEL-positive apoptotic cells in MPTP-treated mice were ameliorated by miR-29c. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 127-131 interleukin 6 Mus musculus 83-87 32305864-6 2020 Under in vivo conditions, the concentrations of IL-1beta, IL-6 and TNF-alpha in PD model group achieved by injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intraperitoneally, were significantly higher than those in the control mouse group. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 120-164 interleukin 6 Mus musculus 58-62 32376269-10 2020 Moreover, MPTP administration increases in the cell number of microglia and astrocytes and the expression of inflammatory factors TNF-alpha, IL-1beta, and IL-6. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 10-14 interleukin 6 Mus musculus 155-159 29363729-4 2018 Flow cytometric analysis indicated that the ratio of CD3+CD4+ to CD3+CD8+ T lymphocytes in the peripheral blood increased in MPTP-treated mice following treatment with EGCG, and EGCG reduced expression of inflammatory factors tumor necrosis factor-alpha and interleukin-6 in serum. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 125-129 interleukin 6 Mus musculus 258-271 26852411-10 2017 SUC also suppressed striatal astroglial activation and increased interleukin-6 levels in MPTP-intoxicated mice. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 89-93 interleukin 6 Mus musculus 65-78 28182002-5 2017 Rapamycin increased interleukin-6 (IL-6) expression, which was associated with reduced expression of inflammatory cytokines, indicating anti-inflammatory properties of IL-6 in the MPTP model. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 180-184 interleukin 6 Mus musculus 35-39 28182002-5 2017 Rapamycin increased interleukin-6 (IL-6) expression, which was associated with reduced expression of inflammatory cytokines, indicating anti-inflammatory properties of IL-6 in the MPTP model. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 180-184 interleukin 6 Mus musculus 168-172